PaclitaxelAntineoplastic Agents, PhytogenicAntineoplastic Combined Chemotherapy ProtocolsCarboplatinDrug Administration ScheduleOvarian NeoplasmsTreatment OutcomeTubulin ModulatorsDose-Response Relationship, DrugInfusions, IntravenousCisplatinAntineoplastic AgentsDrug Resistance, NeoplasmBreast NeoplasmsLung NeoplasmsDoxorubicinTaxoidsBridged CompoundsCell Line, TumorNeutropeniaCarcinoma, Non-Small-Cell LungTaxusDrug SynergismPharmaceutical VehiclesTubulinDeoxycytidineEpothilonesNeoplasmsDisease-Free SurvivalMaximum Tolerated DoseArea Under CurveCombined Modality TherapyDrug Delivery SystemsP-GlycoproteinPeripheral Nervous System DiseasesSurvival AnalysisMice, NudeTime FactorsDrug CarriersAdministration, OralVinblastineEpirubicinMicrotubulesTopotecanApoptosisFallopian Tube NeoplasmsTumor Cells, CulturedSurvival RateXenograft Model Antitumor AssaysDrug-Related Side Effects and Adverse ReactionsNeoplasm StagingNauseaDrug Resistance, MultipleAntibodies, Monoclonal, HumanizedDrug Screening Assays, AntitumorCyclophosphamideNanoparticlesDrug InteractionsLeukopeniaFluorouracilPolyethylene GlycolsThrombocytopeniaFeasibility StudiesAlopeciaHematologic DiseasesIfosfamidePeritoneal NeoplasmsDouble-Blind MethodDrug Therapy, CombinationCell SurvivalChemistry, PharmaceuticalNeoplasms, Glandular and EpithelialChemotherapy, AdjuvantGranulocyte Colony-Stimulating FactorCarcinomaAlbuminsVomitingInhibitory Concentration 50Antibodies, MonoclonalAntibiotics, AntineoplasticMicellesPolyglutamic AcidAdenocarcinomaClinical Trials as TopicCyclosporinsRadiation-Sensitizing AgentsPlatinum CompoundsFollow-Up StudiesDisease ProgressionEstramustineDrug HypersensitivityNeoplasm Recurrence, LocalEtoposideCell ProliferationProspective StudiesDelayed-Action PreparationsInfusions, ParenteralDrug CombinationsAgranulocytosisSalvage Therapy